Clinical trial NCT01268280 (phase 2, status: terminated)
Conditions: myasthenia gravis
ICD codes: P94.0, G70.00, G70.01
Drugs: placebo, 250 mg ck-2017357, 500 mg ck-2017357
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C, CCC(CC)N1C(=O)NC2=NC=C(N=C12)C#C
Reason stopped: 
    closed after complete treatment of 32 patients after 21 months' recruitment.
  
Eligibility criteria:

        Inclusion criteria:

          -  Ability to comprehend and willing to sign an Informed Consent Form (ICF)

          -  Ability to understand written and oral English language

          -  Males and females between 18 and 80 years of age, inclusive

          -  Patient's signs and symptoms not better explained by another disease process

          -  Established diagnosis of MG defined as clinical evidence of muscle weakness and
             positive AChR-binding antibody titer (>0.02 nmol/L)

          -  Myasthenia Gravis Foundation of America (MGFA) clinical classification II or III

          -  Stable MG disease for 4 weeks prior to randomization

          -  Ability to refrain from IVIg treatments during the course of the study

          -  Ability to refrain from cholinesterase-inhibitors (e.g. pyridostigmine) for 12 hours
             before each dose

          -  Ability to perform all elements of the QMG

          -  Grade of 2 or 3 in two or more of the following muscle groups as measured by QMG:
             right or left arm flexion, head lift, and right or left leg raise at 45° Note:
             Patients may re-screen if they fail due to inadequate weakness from taking
             pyridostigmine within 12 hours of screening

          -  Body mass index (BMI) of 18.0 to 36.0 kg/m2, inclusive

          -  Pre-study clinical laboratory findings (including troponin I [TnI] and creatine
             phosphokinase [CPK]) within the normal range, or if outside of the normal range,
             deemed not clinically significant by the Investigator

          -  For female patients only: Agreement to use a double barrier during sexual intercourse
             (1 hormonal, plus 1 barrier method, or 2 simultaneous barrier methods) birth control
             (birth control pills, male condom, female condom, intrauterine device, Norplant, tubal
             ligation, or other sterilization procedures)

          -  For male patients only: Agreement either to use a condom during sexual intercourse
             with female partners who are of reproductive potential and to have female partners use
             an additional effective means of contraception (e.g., diaphragm plus spermicide, or
             oral contraceptives) for the duration of the study and 10 weeks after the end of the
             study or to abstain from sexual intercourse for the duration of the study and 10 weeks
             after the end of the study

        Exclusion criteria:

          -  History of chronic degenerative, psychiatric, or neurologic disorder other than MG
             that can produce weakness or fatigue

          -  Other major chronic or debilitating illnesses within six months prior to study entry

          -  Hepatic insufficiency (defined as ALT or AST > 3x ULN, or total bilirubin > 3 mg/dL)

          -  Renal insufficiency (defined as serum creatinine > 2.5 mg/dL or receiving dialysis)

          -  Other myasthenic syndromes (e.g. Lambert Eaton syndrome; inherited myasthenic
             syndrome)

          -  Female patients who are premenopausal and are: (a) pregnant on the basis of a serum
             pregnancy test, (b) breast-feeding, or (c) not using an effective method of double
             barrier (1 hormonal plus 1 barrier method or 2 simultaneous barrier methods) birth
             control (birth control pills, male condom, female condom, intrauterine device,
             Norplant, tubal ligation, or other sterilization procedures)

          -  Receipt of IVIg or plasmapheresis treatment within 6 weeks prior to the first dose of
             study drug

          -  Changes to immunosuppressive treatments (i.e., prednisone) within 6 weeks prior to the
             first dose of study drug

          -  Rituxan treatment within 3 months prior to study entry

          -  Participation in any other investigational study drug or device trial in which receipt
             of an investigational study drug or device occurred within 30 days prior to dosing

          -  Any prior treatment with CK-2017357

          -  Recent history of alcoholism or drug abuse, or significant behavioral or psychiatric
             problems, or other conditions which in the Investigator's opinion may impair ability
             to adequately comply with the requirements of the study